Glenmark Pharmaceuticals licenses small molecule oncology compound from APC Therapeutics to expand I

The compound has the potential to be used as a monotherapy or in combination with approved therapies to address unmet needs in cancer treatment.

Glenmark Pharmaceuticals has entered into a licensing agreement with Boston-based APC Therapeutics for exclusive rights to a small molecule, oncology compound based on Antigen Presenting Cell (APC) biology. The compound has the potential to be used as a monotherapy or in combination with approved therapies to address unmet needs in cancer treatment.

"This asset adds to our robust biologics pipeline of targeted IO therapies," said Kurt Stoeckli, President and Chief Scientific Officer at Glenmark Pharmaceuticals. "The mechanism of action of APC biology is very intriguing and has the potential to be transformative in cancer treatment by triggering powerful immunologic responses to tumors that may lead to deeper and more durable responses to treatment."

Under the terms of the agreement, Glenmark will license the product from APC Therapeutics, and manage all clinical development including regulatory filings and commercialization worldwide. APC Therapeutics will receive development milestones and sales royalty payments.

"Glenmark is an ideal partner to advance such an important scientific breakthrough treatment to patients with cancer," said Vinod Patel and Venkateshwar Reddy, the co-founders of APC Therapeutics. "This partnership is strategically significant for APC Therapeutics as it validates and advances our commitment to bring the right immunotherapies to the right patient populations."